Microbial and metabolic features in renal transplant recipients with post‐transplantation diabetes mellitus

Abstract

Objective Post‐transplantation diabetes mellitus (PTDM) is a common complication in renal transplant recipients (RTRs). Gut microbiome plays important roles in a variety of chronic metabolic diseases, but its association with the occurrence and development of PTDM is still unknown. The present study integrates the analysis of gut microbiome and metabolites to further identify the characteristics of PTDM. Methods A total of 100 RTRs fecal samples were collected in our study. Among them, 55 samples were submitted to Hiseq sequencing, and 100 samples were used for non‐targeted metabolomics analysis. The gut microbiome and metabolomics of RTRs were comprehensively characterized. Results The species Dialister invisus was significantly associated with fasting plasma glucose (FPG). The functions of tryptophan and phenylalanine biosynthesis were enhanced in RTRs with PTDM, while the functions of fructose and butyric acid metabolism were reduced. Fecal metabolome analysis indicated that RTRs with PTDM had unique metabolite distribution characteristics, and two differentially expressed specific metabolites were significantly correlated with FPG. The correlation analysis of gut microbiome and metabolites showed that gut microbiome had an obvious effect on the metabolic characteristics of RTRs with PTDM. Moreover, the relative abundance of microbial function is associated with the expression of several specific gut microbiome and metabolites. Conclusions Our study identified the characteristics of gut microbiome and fecal metabolites in RTRs with PTDM, and we also found two important metabolites and a bacterium were significantly associated with PTDM, which might be used as novel targets in the research field of PTDM.

Evidence from mendelian randomization identifies several causal relationships between primary membranous nephropathy and gut microbiota

“…Therefore, monitoring Ruminococcus abundance is crucial for pMN prevention and treatment. Dialister invisus has limited discussion in pMN research, although recent studies link it to fasting glucose levels in diabetic renal transplant patients and its dominance in CKD [ 37 , 38 ]. Its impact on intestinal SIgA remains unclear, necessitating further exploration.…”

Longitudinal non-targeted metabolomic profiling of urine samples for monitoring of kidney transplantation patients

“…Specifically, changes in amino acids like HMDB0012266, HMDB0029138, and HMDB0029452, along with lipids, were identified. Previous research linked lysine synthesis disruptions to acute rejection and post-transplant diabetes [ 44 , 45 ]. HMDB0012266, an intermediate in lysine synthesis [ 46 ], showed increased levels in Group 2 compared to Group 1, potentially predicting early graft loss risk.…”